Last reviewed · How we verify
Assessment of the Inter-patient Variability in Clinical Response and Correlated Genetic Variations in Substance Use Disorders
This research outcomes can be summarized as follows: 1. Pharmacogenomic analysis of Substance Use Disorder (SUD) and medications used for the treatment of SUD. 2. Identification of novel genetic variations related to SUD specifically in the Egyptian population. 3. Validation of currently known genetic variations associated with SUD. When the functional interpretation of common or rare variants in studied genes becomes available, such pharmacogenomic information can be used to improve pharmacotherapy individualization.
Details
| Lead sponsor | Alexandria University |
|---|---|
| Status | UNKNOWN |
| Enrolment | 200 |
| Start date | 2022-11-28 |
| Completion | 2024-12 |
Conditions
- Substance Use Disorders
- Substance Dependence
Interventions
- Quetiapine, olanzapine, mirtazapine, carbamazepine, sertraline, amitriptyline, chlorpromazine and risperidone
Primary outcomes
- Pharmacogenomic analysis of SUD and medications used for the treatment of SUD. — 1 year
Countries
Egypt